Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6EQM

Crystal Structure of Human BACE-1 in Complex with CNP520

6EQM の概要
エントリーDOI10.2210/pdb6eqm/pdb
分子名称Beta-secretase 1, ~{N}-[6-[(3~{R},6~{R})-5-azanyl-3,6-dimethyl-6-(trifluoromethyl)-2~{H}-1,4-oxazin-3-yl]-5-fluoranyl-pyridin-2-yl]-3-chloranyl-5-(trifluoromethyl)pyridine-2-carboxamide (3 entities in total)
機能のキーワードstructure-based drug design, alzheimer's disease, aspartic acid proteinase, hydrolase
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数1
化学式量合計45291.13
構造登録者
Rondeau, J.-M.,Wirth, E. (登録日: 2017-10-13, 公開日: 2018-09-19, 最終更新日: 2024-10-16)
主引用文献Neumann, U.,Ufer, M.,Jacobson, L.H.,Rouzade-Dominguez, M.L.,Huledal, G.,Kolly, C.,Luond, R.M.,Machauer, R.,Veenstra, S.J.,Hurth, K.,Rueeger, H.,Tintelnot-Blomley, M.,Staufenbiel, M.,Shimshek, D.R.,Perrot, L.,Frieauff, W.,Dubost, V.,Schiller, H.,Vogg, B.,Beltz, K.,Avrameas, A.,Kretz, S.,Pezous, N.,Rondeau, J.M.,Beckmann, N.,Hartmann, A.,Vormfelde, S.,David, O.J.,Galli, B.,Ramos, R.,Graf, A.,Lopez Lopez, C.
The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.
EMBO Mol Med, 10:-, 2018
Cited by
PubMed Abstract: The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of amyloid-β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti-Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states. The BACE-1 inhibitor CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies. CNP520 reduced brain and cerebrospinal fluid (CSF) Aβ in rats and dogs, and Aβ plaque deposition in APP-transgenic mice. Animal toxicology studies of CNP520 demonstrated sufficient safety margins, with no signs of hair depigmentation, retina degeneration, liver toxicity, or cardiovascular effects. In healthy adults ≥ 60 years old, treatment with CNP520 was safe and well tolerated and resulted in robust and dose-dependent Aβ reduction in the cerebrospinal fluid. Thus, long-term, pivotal studies with CNP520 have been initiated in the Generation Program.
PubMed: 30224383
DOI: 10.15252/emmm.201809316
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.35 Å)
構造検証レポート
Validation report summary of 6eqm
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon